Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.

Anti-cancer drugs - 1 Sept 2026

Sun Qiong, Du Sicheng, Meng Jing, Shi Weiwei

Abstract excerpt

Scirrhous gastric cancer (SGC), including the Borrmann type IV subtype, is characterized by a desmoplastic stroma, rapid progression, and a poor prognosis with limited effective treatment options. While fibroblast growth factor receptor 2 (FGFR2) alterations are recognized therapeutic targets in some cancers, their clinical application in gastric cancer, particularly in SGC, remains underexplored. We present the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Morpholines
Share to Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrazoles

Share to Pyrimidines

Share to Pyrroles

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Stomach Neoplasms

Source

Identifiers

PMID: 41563935
DOI: 10.1097/CAD.0000000000001807

Genes

FGFR2
FGFR1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.PMID 41563935Read ↗

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read ↗

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancerSemantic proximity Read ↗

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.Semantic proximity Read ↗

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.Semantic proximity Read ↗

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.Semantic proximity Read ↗

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Semantic proximity Read ↗

FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohortSemantic proximity Read ↗

Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.Semantic proximity Read ↗

Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review.Semantic proximity Read ↗

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.Semantic proximity Read ↗

Sustained Response on Sequential Anti-fgfr Therapy in Metastatic Gall Bladder Cancer - a Case Report and Literature ReviewSemantic proximity Read ↗

FGFR2 and favorable survival outcomes in resected poorly cohesive cell gastric cancer: Analysis from FGFR2 protein overexpression and genetic variation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.